Clients

Take a look at our work and the interviews that show how we help our clients grow. The Lavery Signature is our commitment to a strategic partnership where we put your success first. 

  1. Client work

    Lavery Advises inBeat Agency its financing with BDC and the Acquisition of Creative Milkshake

    Lavery is proud to have advised inBeat Agency on its financing with the BDC, as well as on the acquisition of Creative Milkshake. This major transaction represents a significant milestone in inBeat’s growth trajectory and further consolidates its position within an ecosystem where influencer marketing, content creation and digital performance converge. Beyond the strategic expansion it enables, this deal brings together two talented teams with complementary expertise: inBeat, led by co-founders David Morneau and Daniel Cruz, among others, and Creative Milkshake, led by Mirella Crespi. The combined strengths of these teams enhance the group’s ability to innovate, expand its reach in Canada and internationally, and generate greater value for its clients. The mandate was handled by a Lavery team led by Jean-François Maurice and comprising Rodrigo Olmos-Hortigüela, Éric Gélinas and Julie Aubin-Perron. We would like to thank the team at inBeat Agency for their trust, as well as all parties involved for their support throughout the process. Our congratulations to inBeat Agency, Creative Milkshake and all the teams involved for this strategic achievement and the ambitious vision behind it.

    Read more

  2. Client work

    Lavery represented Formedica in the acquisition of Masdel Inc.

    We were delighted to represent Formedica in the acquisition of Masdel Inc., a reputable business specializing in the development of health, wellness and beauty products. This strategic transaction will enable Formedica to strengthen its market position and accelerate growth in a rapidly evolving sector. The deal also highlights the strong momentum in Quebec’s innovative health and specialty product sector. Lavery supported Formedica throughout the entire process, leveraging a multidisciplinary team led by Francis Dumoulin, with contributions from Siddhartha Borissov Beausoleil, Isabelle Jomphe, Jessica Parent, Sarah Trublard, Sophie Poirier, Arielle Supino, Elissa Louka and Alex-Anne Trudeau. This transaction illustrates the strategic importance of business transfers in preserving and growing Quebec’s assets. Lavery has a long history of assisting entrepreneurs and business buyers through such pivotal transitions, ensuring business continuity, protecting investments, and creating long-term value. We extend our sincere thanks to Formedica for entrusting our team with a strategic transaction that will fuel its future growth. Find out more here: https://www.newswire.ca/fr/news-releases/formedica-procede-a-l-acquisition-de-masdel-863570670.html

    Read more

  3. Client work

    Successful transaction: Progression joins Valsoft Corporation

    We are pleased to announce the acquisition of Progression by Valsoft Corporation, an operation that underscores both companies' commitment to strengthening their position in the dynamic service management sector. This strategic partnership will allow Progression to continue its growth trajectory while preserving its independence and entrepreneurial spirit for which it is renowned. At Lavery, we are proud to stand by our clients during these crucial stages. Every decision made in the context of this transaction shapes the future and professional success of our clients. The Lavery team was led by Alexandre Hébert and composed of Siddhartha Borissov-Beausoleil, Francis Dumoulin, Jean-Paul Timothée, Diane L'Écuyer, and Arielle Supino.  Valsoft, on the other hand, was internally represented by Shinjay (Ssin) Choi, Senior Legal Counsel, and Elisa Maria M., Senior Corporate Paralegal. The financial dimension of this acquisition was orchestrated by Raymond Chabot Grant Thornton, under the expert direction of Simon Marcotte Légaré, MBA, partner in mergers and acquisitions.  

    Read more

  4. Client work

    Lavery helps Cultures Gen V become Quebec’s largest greenhouse grower

    On July 4, 2023, Cultures Gen V, one of Quebec’s leading greenhouse growers, announced the acquisition of Serres Royales. The acquisition furthers Cultures Gen V’s business strategy, which aims to improve Quebec’s food self-sufficiency by expanding sustainable greenhouse growing and offering consumers a wider variety of superior quality products. This transaction makes Cultures Gen V the largest diversified greenhouse grower in Quebec, adding 9 hectares of tomatoes to its current acreage, for a total of 36 hectares. Lavery was privileged to represent Cultures Gen V in the transaction. Not only did the firm implement the group’s pre-transaction refinancing, it also negotiated and closed the transaction. The Lavery team was led by Étienne Brassard with the assistance of Gabrielle Ahélo and France Camille De Mers and the collaboration of Béatrice Bull, Pamela Cifola, Éric Gélinas, Jessica Parent, Chantal Desjardins, James Duffy, Valérie Belle-Isle, Sonia Guérin, Joseph Lauzon-Potts, Arielle Supino, Bernard Trang, Katerina Kostopoulos, Charlotte Dangoisse, David Tournier, Ana Cristina Nascimento, Joëlle Montpetit and Nadine Giguère.

    Read more

  5. Client work

    Lavery assists Fancamp Exploration Ltd. in a joint venture agreement with Platinex Inc.

    On March 13, 2023, Fancamp Exploration Ltd. (Fancamp) officially announced that it had entered into a joint venture agreement with Platinex Inc. (Platinex) to further explore and promote certain gold mining properties located in Ontario and owned by the two entities. The transaction involved Fancamp transferring its Heenan Mallard and Dorothy mining properties to South Timmins Mining Inc. (Goldco), a wholly-owned subsidiary of Platinex, in exchange for shares representing 25% of Goldco's issued and outstanding shares and a 1% royalty on the properties to Platinex. The transaction also included a shareholder agreement providing for the governance of Goldco's activities. Fancamp subscribed for a number of shares representing 9.5% of Platinex's issued and outstanding shares. Lavery was privileged to represent Fancamp in this important mandate led by Jean-Paul Timothée and Alexandre Turcotte. -- Fancamp is a growing Canadian mineral exploration corporation dedicated to its value-added strategy of advancing its priority mineral properties through exploration and innovative development. The corporation owns numerous mineral resource properties in Quebec, Ontario and New Brunswick, where it mines chromium sector, strategic rare-earth metals, gold, zinc, titanium and other resources. To learn more about Fancamp, go to: https://www.fancamp.ca

    Read more

  6. Client work

    Lavery represents ImmunoPrecise Antibodies as it acquires BioStrand

    On March 29, 2022, ImmunoPrecise Antibodies Ltd (IPA) announced that it acquired BioStrand BV, BioKey BV, and BioClue BV (together, “BioStrand”), a group of Belgian entities pioneers in the field of bioinformatics and biotechnology. With this €20 million acquisition, IPA will be able to leverage BioStrand’s revolutionary AI-powered methodology to accelerate the development of therapeutic antibody solutions. In addition to creating synergies with its subsidiaries, IPA expects to develop new markets with this revolutionary technology and strengthen its position as a world leader in biotherapeutics. Lavery was privileged to support IPA in this cross-border transaction by providing specialized expertise in cybersecurity, intellectual property, securities and mergers and acquisitions. The Lavery team was led by Selena Lu (transactional) and included Eric Lavallée (technology and intellectual property), Serge Shahinian (intellectual property), Sébastien Vézina (securities), Catherine Méthot (transactional), Jean-Paul Timothée (securities and transactional), Siddhartha Borissov-Beausoleil (transactional), Mylène Vallières (securities) and Marie-Claude Côté (securities). ImmunoPrecise Antibodies Ltd. is a biotherapeutic, innovation-powered company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of target classes and diseases.

    Read more